MannKind Corporation ( (MNKD) ) has released its Q3 earnings. Here is a breakdown of the information MannKind Corporation presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
MannKind Corporation is a biopharmaceutical company focused on developing and commercializing innovative therapies for chronic diseases, particularly in the cardiometabolic and orphan lung disease sectors. In its third quarter of 2025, MannKind reported a revenue increase of 17% compared to the same period in 2024, reaching $82.1 million. The company also completed the acquisition of scPharmaceuticals, which is expected to accelerate revenue growth through FUROSCIX, a therapy for edema associated with chronic heart failure and kidney disease. Key financial highlights include a 23% increase in Afrezza sales and a 14% year-to-date revenue growth. MannKind’s strategic initiatives include the FDA’s acceptance of Afrezza’s pediatric sBLA, the submission of FUROSCIX ReadyFlow Autoinjector sNDA, and progress in clinical trials for MNKD-101 and MNKD-201. Looking ahead, MannKind’s management remains optimistic about the company’s growth prospects, driven by its diversified portfolio and ongoing clinical developments.